DIN EN ISO 20916:2024-07 (E)

In vitro diagnostic medical devices - Clinical performance studies using specimens from human subjects - Good study practice (ISO 20916:2019)

Contents

Page

European foreword ... **4**

Annex ZA (informative) **Relationship between this European Standard the General Safety and Performance Requirements of Regulation (EU) 2017/746 aimed to be covered** ... **5**

Foreword ... **9**

Introduction ... **10**

1 Scope ... **12**

2 Normative references ... **12**

3 Terms and definitions ... **13**

4 Ethical considerations ... **22**
4.1 General ... 22
4.2 Improper influence or inducement ... 22
4.3 Responsibilities ... 22
4.4 Ethics committee involvement ... 22
4.5 Informed consent ... 23

5 Clinical performance study planning ... **23**
5.1 General ... 23
5.2 Risk evaluation ... 24
5.3 Design of the clinical performance study ... 25
5.4 Investigator brochure ... 25
5.5 Clinical Performance Study Protocol (CPSP) ... 26
5.5.1 General ... 26
5.5.2 Principal investigator responsibilities ... 26
5.5.3 Contents of the CPSP ... 27
5.6 Case report forms ... 30
5.7 Recording of specimen information ... 31
5.8 Specimen accountability and integrity ... 31
5.9 Study site selection ... 31
5.9.1 Site qualification ... 31
5.9.2 Site assessment ... 31
5.9.3 Site selection ... 31
5.10 Monitoring plan ... 32
5.11 Agreements ... 32
5.12 Labelling ... 32

6 Study site initiation ... **32**
6.1 General ... 32
6.2 Prerequisites ... 33
6.3 Training ... 33
6.4 Initiation of the study site ... 33

7 Clinical performance study conduct ... **34**
7.1 General ... 34
7.2 Responsibilities of the sponsor ... 34
7.3 Study site monitoring ... 34
7.3.1 General ... 34
7.3.2 Routine monitoring ... 34

7.3.3 Monitoring reports 35
7.4 Security and confidentiality of data 36
8 Close-out of the clinical performance study 36
8.1 Close-out activities 36
8.2 Clinical performance study report 36
8.3 Document retention 38
8.4 Suspension or premature termination of the clinical performance study 38
9 Auditing 39
Annex A (normative) **Additional general requirements for certain studies 40**
Annex B (normative) **Clinical performance study protocol (CPSP) 43**
Annex C (normative) **Investigator brochure 47**
Annex D (normative) **Clinical performance study report 49**
Annex E (normative) **Communication with the ethics committee 52**
Annex F (normative) **Informed consent 54**
Annex G (normative) **Adverse event categorization 58**
Annex H (informative) **Good clinical performance study documentation 62**
Annex I (informative) **Auditing 67**
Bibliography 68